Teva Pharmaceutical Industries Ltd. — Director's Dealing 2025

Jun 9, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK: 0000818686
Period of Report: 2025-06-05

Reporting Person: LIEBERMAN GERALD M (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-06-06	Ordinary Shares	M	9632	—	Acquired	115657	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-06	Restricted Share Units	$	M	9632	Disposed		Ordinary Shares (9632)	Direct
2025-06-05	Restricted Share Units	$	A	14492	Acquired		Ordinary Shares (14492)	Direct

Footnotes

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025.

F4: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026.